During the past decade, Texas Oncology, P.A. conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 10 clinical trials were completed, i.e. on average, 111.1% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 5 clinical trials were completed. i.e. 250% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Texas Oncology, P.A." #1 sponsor was "Bristol-Myers Squibb" with 4 trials, followed by "US Oncology Research" with 4 trials sponsored, "Eisai Inc." with 2 trials sponsored, "Astellas Pharma Inc" with 1 trials sponsored and "G1 Therapeutics, Inc." with 1 trials sponsored. Other sponsors include 5 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Texas Oncology, P.A." #1 collaborator was "Sanofi" with 2 trials as a collaborator, "US Oncology Research" with 2 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator, "Eisai Limited" with 1 trials as a collaborator and "OSI Pharmaceuticals" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "Texas Oncology, P.A." are "Metastatic Breast Cancer" (7 trials), "Breast Cancer" (5 trials), "Non-Small Cell Lung Cancer" (2 trials), "Prostate Cancer" (2 trials) and "Advanced Breast Cancer" (1 trials). Many other conditions were trialed in "Texas Oncology, P.A." in a lesser frequency.

Most popular intervention types in "Texas Oncology, P.A." are "Drug" (18 trials), "Other" (3 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Carboplatin" (3 trials), "Bevacizumab" (2 trials), "Docetaxel" (2 trials), "Gemcitabine" (2 trials) and "Ixabepilone" (2 trials). Other intervention names were less common.

The vast majority of trials in "Texas Oncology, P.A." are 11 trials for "All" genders, 7 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Texas Oncology, P.A.". undefined are not yet recruiting, 1 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 18 completed trials in Texas Oncology, P.A., undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Texas Oncology, P.A., 1 "Phase 1" clinical trials were conducted, 12 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".